|Articles|April 1, 2013
- BioPharm International-04-01-2013
- Volume 26
- Issue 4
BioPharm International, April 2013 Issue (PDF)
Click the title above to open the BioPharm International April 2013 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 13 years ago
Milestones and Moderate Progress in 2012 Drug Approvalsalmost 13 years ago
Custom-Cell Products: Diversified In Vitro Modelsalmost 13 years ago
Benchmarking: Don't Just Run the Numbers, Understand the Processalmost 13 years ago
Strategic Partnering for Manufacturingalmost 13 years ago
State of Quality and Compliance in the Biopharmaceutical Industryalmost 13 years ago
Navigating Emerging Markets — Latin Americaalmost 13 years ago
Analytical Method Lifecycle: A Roadmap for Biopharmaceutical Developmentalmost 13 years ago
Manufacturers Under Pressure to Manage Painkillersalmost 13 years ago
Prescribing Caution for Biosimilarsalmost 13 years ago
Financing InnovationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5
